Privium Fund Management B.V. Purchases 3,596 Shares of Voyager Therapeutics, Inc. $VYGR

Privium Fund Management B.V. grew its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 16.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 25,241 shares of the company’s stock after buying an additional 3,596 shares during the period. Privium Fund Management B.V.’s holdings in Voyager Therapeutics were worth $79,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Armistice Capital LLC raised its holdings in Voyager Therapeutics by 0.7% in the 1st quarter. Armistice Capital LLC now owns 5,436,000 shares of the company’s stock worth $18,374,000 after acquiring an additional 40,000 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Voyager Therapeutics by 1.6% in the 1st quarter. Vestal Point Capital LP now owns 1,249,418 shares of the company’s stock worth $4,223,000 after purchasing an additional 19,418 shares in the last quarter. Erste Asset Management GmbH increased its holdings in shares of Voyager Therapeutics by 5.5% in the 1st quarter. Erste Asset Management GmbH now owns 1,116,793 shares of the company’s stock worth $3,826,000 after purchasing an additional 58,415 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after purchasing an additional 317,927 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in shares of Voyager Therapeutics by 863.3% during the first quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares in the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on VYGR. Wedbush decreased their target price on Voyager Therapeutics from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research note on Monday, September 15th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Voyager Therapeutics in a report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $12.96.

Voyager Therapeutics Trading Up 2.4%

Shares of NASDAQ VYGR opened at $5.07 on Tuesday. The firm has a 50 day moving average of $4.21 and a 200 day moving average of $3.57. The firm has a market capitalization of $281.23 million, a price-to-earnings ratio of -2.74 and a beta of 0.95. Voyager Therapeutics, Inc. has a 12-month low of $2.64 and a 12-month high of $8.17.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%.The business had revenue of $5.20 million for the quarter, compared to analysts’ expectations of $9.50 million. Sell-side analysts predict that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In related news, CFO Nathan D. Jorgensen sold 7,666 shares of the company’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $4.78, for a total value of $36,643.48. Following the completion of the transaction, the chief financial officer owned 123,834 shares of the company’s stock, valued at approximately $591,926.52. This represents a 5.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.